Figure 6. Dual blockade of AKT and EGFR have beneficial effects on AKT and MAPK activity. CtxR cells (HC1, HC4, HC8) were plated and treated with the DMSO (vehicle), 100 nM cetuximab, 5 uM MK-2206 or the combination (cetuximab+MK-2206) for 24 h. Cells were harvested and protein was collected, fractionated by SDS-PAGE and immunoblotted for the indicated proteins. α-Tubulin was used as a loading control.